Q1 2026 Roivant Sciences Ltd Earnings Call Transcript
Key Points
- Roivant Sciences Ltd (ROIV) has initiated the Phase 3 study in cutaneous sarcoidosis for brepocitinib ahead of schedule, following strong Phase 2 data showing a >20-point benefit on the CSAMI scale versus placebo.
- The company is on track for the potential launch of brepocitinib in dermatomyositis by the end of September, with priority review and a fully built commercial team ready to deploy.
- Roivant Sciences Ltd (ROIV) received the initial $950 million payment from the Moderna settlement, with $772 million going to Genevant, strengthening its cash position to nearly $4 billion.
- The company has filed international lawsuits against Pfizer and BioNTech in Canada and the UPC, advancing its litigation strategy for additional potential recoveries.
- Roivant Sciences Ltd (ROIV) continues to execute on its share repurchase program, buying back shares at an average price in the high $20s since March, returning capital to shareholders.
- The pipeline is advancing with multiple upcoming catalysts, including top-line data from the NIU study, the Mosley Phase 3 study in PH-ILD, and the D2T RA program at Immunovant, all expected in the second half of 2026.
- Roivant Sciences Ltd (ROIV) expects a 'slow and steady' launch for brepocitinib in dermatomyositis, which may not meet investor expectations for rapid revenue growth.
- The company faces uncertainty in the PH-ILD program, with the Phase 3 study not powered for six-minute walk distance, and the potential for unexpected results in translating PVR reductions from PAH to PH-ILD.
- There is a risk of high placebo response rates in the NIU Phase 3 study, which could impact the trial's ability to show a statistically significant benefit.
- Roivant Sciences Ltd (ROIV) has not provided specific metrics or guidance for tracking the DM launch, leaving investors without clear benchmarks to assess early performance.
- The company's R&D expenses remain high at approximately $200 million for the quarter, with significant ongoing investment in multiple programs, which could pressure near-term profitability.
- The D2T RA program faces a higher bar for success in the randomized withdrawal phase due to strong open-label response rates, and the company is still awaiting FDA feedback to finalize the pivotal study design.
Good day and thank you for standing by. Welcome to Roivant first-quarter 2026 earnings conference call. (Operator Instructions) Please be advised that today's call is being recorded.
I'd now like to hand the conference over to your first speaker today, Stephanie Lee. Thank you. Please go ahead.
Good morning, and thanks for joining today's call to review Roivant's financial results for the first quarter ended June 30, 2026. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant. For those diving in via conference call, you can find the slides being presented today, as well as the press release announcing these updates on our IR website at www.investor.roivant.com.
We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
